A Review on the Effect of COVID-19 in Type 2 Asthma and Its Management

Overview

Journal Int Immunopharmacol

Specialties Allergy & Immunology
Pharmacology

Date 2021 Jan 1

PMID 33385710

Citations 8

Authors

Srijit Ghosh

Srijita Das

Rupsa Mondal

Salik Abdullah

Shirin Sultana

Sukhbir Singh

Aayush Sehgal

Tapan Behl

Affiliations

Soon will be listed here.

Abstract

Background: COVID-19 is considered the most critical health pandemic of 21st century. Due to extremely high transmission rate, people are more susceptible to viral infection. COVID-19 patients having chronic type-2 asthma prevails a major risk as it may aggravate the disease and morbidities.

Objective: The present review mainly focuses on correlating the influence of COVID-19 in type-2 asthmatic patients. Besides, it delineates the treatment measures and drugs that can be used to manage mild, moderate, and severe symptoms of COVID-19 in asthmatic patients, thus preventing any exacerbation.

Methods: An in-depth research was carried out from different peer-reviewed articles till September 2020 from several renowned databases like PubMed, Frontier, MEDLINE, and related websites like WHO, CDC, MOHFW, and the information was analysed and written in a simplified manner.

Results: The progressive results were quite conflicting as severe cases of COVID-19 shows an increase in the level of several cytokines that can augment inflammation to the bronchial tracts, worsening the asthma attacks. Contradicting to this, certain findings reveal the decrease in the severity of COVID-19 due to the elevation of T-cells in type-2 asthmatic patients, as prominent reduction of T-cell is seen in most of the COVID-19 positive patients. This helps to counteract the balance of immune responses and hence ameliorate the disease progression.

Conclusion: Asthmatic patients must remain cautious during the COVID-19 pandemic by maintaining all the precautions to stay safe due to limited research data. Future strategies should include a better understanding of asthmatic exacerbation and its relation to COVID-19.

Citing Articles

Assessing post-COVID-19 respiratory dynamics: a comprehensive analysis of pulmonary function, bronchial hyperresponsiveness and bronchodilator response.

Huang C, Wu Y, Yang M, Huang K, Su W, Huang Y ERJ Open Res. 2024; 10(5).

PMID: 39377091 PMC: 11456966. DOI: 10.1183/23120541.00149-2024.

Comprehensive Analysis of Disease Pathology in Immunocompetent and Immunocompromised Hosts following Pulmonary SARS-CoV-2 Infection.

Ramasamy S, Kolloli A, Kumar R, Husain S, Soteropoulos P, Chang T Biomedicines. 2022; 10(6).

PMID: 35740365 PMC: 9219777. DOI: 10.3390/biomedicines10061343.

Asthma and coronavirus disease 2019-related outcomes in hospitalized patients: A single-center experience.

Ludwig A, Brehm C, Fung C, Jia S, Troost J, Leuenberger L Ann Allergy Asthma Immunol. 2022; 129(1):79-87.e6.

PMID: 35342017 PMC: 8944118. DOI: 10.1016/j.anai.2022.03.017.

Passive Samplers, an Important Tool for Continuous Monitoring of the COVID-19 Pandemic.

Jiang A, Nian F, Chen H, McBean E Environ Sci Pollut Res Int. 2022; 29(22):32326-32334.

PMID: 35137317 PMC: 9072756. DOI: 10.1007/s11356-022-19073-6.

Long-Term Follow-Up of a Severe Eosinophilic Asthmatic Patient With Comorbid Nasal Polyposis Hospitalized for SARS-CoV-2 Infection While Receiving Benralizumab: A Case Report.

Ambrosino A Cureus. 2022; 13(12):e20364.

PMID: 35036198 PMC: 8752115. DOI: 10.7759/cureus.20364.

References

Rao D, Phipatanakul W . Impact of environmental controls on childhood asthma. Curr Allergy Asthma Rep. 2011; 11(5):414-20. PMC: 3166452. DOI: 10.1007/s11882-011-0206-7. View

Wang F, Tang X, Wei C, Xu L, Mao H, Luo F . Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis. J Dermatol Sci. 2018; 90(2):190-198. DOI: 10.1016/j.jdermsci.2018.01.016. View

Emma R, Morjaria J, Fuochi V, Polosa R, Caruso M . Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience. Ther Adv Respir Dis. 2018; 12:1753466618808490. PMC: 6204623. DOI: 10.1177/1753466618808490. View

Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y . Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020; 71(16):2027-2034. PMC: 7184337. DOI: 10.1093/cid/ciaa344. View

Zein J, Erzurum S . Asthma is Different in Women. Curr Allergy Asthma Rep. 2015; 15(6):28. PMC: 4572514. DOI: 10.1007/s11882-015-0528-y. View

Li W, Gao P, Zhi Y, Xu W, Wu Y, Yin J . Periostin: its role in asthma and its potential as a diagnostic or therapeutic target. Respir Res. 2015; 16:57. PMC: 4437675. DOI: 10.1186/s12931-015-0218-2. View

Mortaz E, Amani S, Mumby S, Adcock I, Movassaghi M, Folkerts J . Role of Mast Cells and Type 2 Innate Lymphoid (ILC2) Cells in Lung Transplantation. J Immunol Res. 2018; 2018:2785971. PMC: 6232810. DOI: 10.1155/2018/2785971. View

Dhama K, Patel S, Sharun K, Pathak M, Tiwari R, Yatoo M . SARS-CoV-2 jumping the species barrier: Zoonotic lessons from SARS, MERS and recent advances to combat this pandemic virus. Travel Med Infect Dis. 2020; 37:101830. PMC: 7396141. DOI: 10.1016/j.tmaid.2020.101830. View

Pelaia C, Paoletti G, Puggioni F, Racca F, Pelaia G, Canonica G . Interleukin-5 in the Pathophysiology of Severe Asthma. Front Physiol. 2020; 10:1514. PMC: 6927944. DOI: 10.3389/fphys.2019.01514. View

10.

Scherzer R, Grayson M . Heterogeneity and the origins of asthma. Ann Allergy Asthma Immunol. 2018; 121(4):400-405. PMC: 6237278. DOI: 10.1016/j.anai.2018.06.009. View

11.

Colice G . Categorizing asthma severity: an overview of national guidelines. Clin Med Res. 2005; 2(3):155-63. PMC: 1069088. DOI: 10.3121/cmr.2.3.155. View

12.

Oliphant C, Barlow J, McKenzie A . Insights into the initiation of type 2 immune responses. Immunology. 2011; 134(4):378-85. PMC: 3230792. DOI: 10.1111/j.1365-2567.2011.03499.x. View

13.

Divekar R, Kita H . Recent advances in epithelium-derived cytokines (IL-33, IL-25, and thymic stromal lymphopoietin) and allergic inflammation. Curr Opin Allergy Clin Immunol. 2014; 15(1):98-103. PMC: 4346181. DOI: 10.1097/ACI.0000000000000133. View

14.

Imbert I, Snijder E, Dimitrova M, Guillemot J, Lecine P, Canard B . The SARS-Coronavirus PLnc domain of nsp3 as a replication/transcription scaffolding protein. Virus Res. 2008; 133(2):136-48. PMC: 7114086. DOI: 10.1016/j.virusres.2007.11.017. View

15.

Barrios R, Kheradmand F, Batts L, Corry D . Asthma: pathology and pathophysiology. Arch Pathol Lab Med. 2006; 130(4):447-51. DOI: 10.5858/2006-130-447-APAP. View

16.

Gras D, Chanez P, Vachier I, Petit A, Bourdin A . Bronchial epithelium as a target for innovative treatments in asthma. Pharmacol Ther. 2013; 140(3):290-305. DOI: 10.1016/j.pharmthera.2013.07.008. View

17.

Prajapat M, Sarma P, Shekhar N, Avti P, Sinha S, Kaur H . Drug targets for corona virus: A systematic review. Indian J Pharmacol. 2020; 52(1):56-65. PMC: 7074424. DOI: 10.4103/ijp.IJP_115_20. View

18.

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y . Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020; 382(13):1199-1207. PMC: 7121484. DOI: 10.1056/NEJMoa2001316. View

19.

Atal S, Fatima Z . IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?. Pharmaceut Med. 2020; 34(4):223-231. PMC: 7292936. DOI: 10.1007/s40290-020-00342-z. View

20.

Wollenberg A, Howell M, Guttman-Yassky E, Silverberg J, Kell C, Ranade K . Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2018; 143(1):135-141. DOI: 10.1016/j.jaci.2018.05.029. View